Why IMI matters to Europe’s pharmaceutical industry – a PPP success story

Magda Chlebus
Director Science Policy, EFPIA
Drug development
R&D cost vs productivity

European Union and EFPIA CEOs joined forces to make drug development in the EU more innovative and efficient by forming the biggest PPP in Life Science (adopted on December 20, 2007 by the European Council).
R&D bottlenecks

Societal needs

Innovative Medicines Initiative
Looking forward

- Combination therapy
- Extreme phenotypes
- Beyond HTS
- Taxonomy
- Stem cells
- EU med info system

Knowledge Management infrastructure and services

- Idea generation
- Basic Research and non clinical testing
- Clinical studies
- Regulatory approval
- HTA & pharmacovigilance
• Proof of concept for new public private collaborations in pharmaceuticals
• Open collaboration to define address common challenges
• A neutral platform for dialogue defining common agenda/priorities
• IMI works: tangible deliverables after less than 2 years – a pace that no other funding scheme allows
• IMI connects the dots between science, health and growth
Thank you!